Why Boston Scientific (BSX) Shares Are Trading Higher Today - Boston Scientific (NYSE:BSX)

Boston Scientific Corp BSX generated Q4 revenues of $3.24 billion, in line with the Wall Street estimate.
Sales increased 3.7% Y/Y on a reported basis, 8.7% on an operational basis, and 7.1% on an organic basis.
The company achieved an adjusted EPS of $0.45, missing the consensus of $0.47.
Revenues from MedSurg increased 4.5% to $1.29 billion (8.5% organic), and the Cardiovascular segment generated $2 billion, +6.4% (9.4% organic).
Also Read: Boston Scientific Adds 'Novel' Technology Via This Acquisition For Interventional Oncology.
The adjusted gross margin remained unchanged at almost 71%, with an adjusted operating income margin of 26%.
Outlook: Boston Scientific estimates Q1 FY3 adjusted EPS of $0.42-$0.44 versus the consensus of $0.44
The company sees the FY23 adjusted EPS of $1.86-$1.93 versus the Wall Street Estimate of $1.93.
The company estimates FY23 sales growth of approximately 5-7% on a reported basis and approximately 6-8% organically.
For Q1, Boston Scientific expects sales growth of 3-5% (6-8% organic).
Price Action: BSX shares are up 2.55 at $47.43 on the last check Wednesday.

Why Boston Scientific Shares Are Trading Higher Today